A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with ovarian cancer susceptibility

Yan,Shi; Yuan,Cunzhong; Yang,Qifeng; Li,Xiaoyan; Yang,Ning; Liu,Xiaoyan; Dong,Ruihua; Zhang,Xi; Yuan,Zeng; Zhang,Ning; Kong,Beihua

doi:10.3892/or.2015.4179

A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with ovarian cancer susceptibility

Authors:
- Shi Yan
- Cunzhong Yuan
- Qifeng Yang
- Xiaoyan Li
- Ning Yang
- Xiaoyan Liu
- Ruihua Dong
- Xi Zhang
- Zeng Yuan
- Ning Zhang
- Beihua Kong
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong, P.R. China, Department of Breast Surgery, Qilu Hospital of Shandong University, Ji'nan, Shandong, P.R. China
Published online on: August 5, 2015 https://doi.org/10.3892/or.2015.4179
Pages: 2151-2155

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Calcium-sensing receptor (CaSR) is a G-protein‑ coupled receptor that senses blood calcium. In vivo, CaSR is required for normal epidermal differentiation by mediating calcium signaling. CaSR was confirmed to be a tumor suppressor in colon and breast cancer. The single-nucleotide polymorphism (SNP) rs17251221, located on the intron, is a genetic variation of the CaSR gene. We analyzed rs17251221 in ovarian cancer using an allelic discrimination assay. Cycling probes were used for genotyping 290 ovarian cancer patients and 312 age-matched cancer-free females. rs17251221 and clinicopathological characteristics of ovarian cancer were analyzed statistically. The AG and GG genotypes were confirmed to appear in fewer cancer cases than in controls and the genotype distribution between cases and controls was statistically significant. The AG+GG genotype was correlated with low ovarian cancer risk, while rs17251221 was not associated with clinicopathological variables including age at diagnosis, tumor size, histologic type, pathological subtype, lymph node metastasis, CA-125 expression, clinical stage, or degree of differentiation. The rs17251221 polymorphism genotype was not correlated with survival in ovarian cancer. These results suggest that the G allele of the CaSR rs17251221 polymorphism is protective against ovarian cancer and the homozygous GG genotype may be a protective genotype as well. The rs17251221 may play an important role in the development of ovarian cancer and could be used as a biomarker for predicting ovarian cancer.

View Figures

View References

1	Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer screening in the United States, 2015: A review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Wang M, He Y, Shi L and Shi C: Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 32:171–177. 2011.PubMed/NCBI
4	American College of Obstetricians and Gynecologists Committee on Gynecologic Practice: Committee opinion no. 477: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 117:742–746. 2011. View Article : Google Scholar : PubMed/NCBI
5	Sueblinvong T and Carney ME: Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol. 10:67–81. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zheng L, Song A, Ruan Y, Chen L, Liu D, Li X, Guo H, Han J, Li Y, Tian X, et al: Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women. Cancer Epidemiol. 37:639–646. 2013. View Article : Google Scholar : PubMed/NCBI
7	Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M and Jagodzinski PP: An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population. Mol Diagn Ther. 18:85–91. 2014. View Article : Google Scholar :
8	Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J and Hebert SC: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 366:575–580. 1993. View Article : Google Scholar : PubMed/NCBI
9	Vezzoli G, Terranegra A, Arcidiacono T, Gambaro G, Milanesi L, Mosca E and Soldati L; GENIAL network (Genetics and Environment in Nephrolithiasis Italian Alliance): Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region. Nephrol Dial Transplant. 25:2245–2252. 2010. View Article : Google Scholar : PubMed/NCBI
10	Pearce SH and Thakker RV: The calcium-sensing receptor: Insights into extracellular calcium homeostasis in health and disease. J Endocrinol. 154:371–378. 1997. View Article : Google Scholar : PubMed/NCBI
11	Brown EM and Hebert SC: Calcium-receptor-regulated parathyroid and renal function. Bone. 20:303–309. 1997. View Article : Google Scholar : PubMed/NCBI
12	Tu CL, Oda Y, Komuves L and Bikle DD: The role of the calcium-sensing receptor in epidermal differentiation. Cell Calcium. 35:265–273. 2004. View Article : Google Scholar : PubMed/NCBI
13	Hendy GN, D'Souza-Li L, Yang B, Canaff L and Cole DE: Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 16:281–296. 2000. View Article : Google Scholar : PubMed/NCBI
14	Rodland KD: The role of the calcium-sensing receptor in cancer. Cell Calcium. 35:291–295. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jorde R, Schirmer H, Njølstad I, Løchen ML, Bøgeberg Mathiesen E, Kamycheva E, Figenschau Y and Grimnes G: Serum calcium and the calcium-sensing receptor polymorphism rs17251221 in relation to coronary heart disease, type 2 diabetes, cancer and mortality: The Tromsø Study. Eur J Epidemiol. 28:569–578. 2013. View Article : Google Scholar : PubMed/NCBI
16	O'Seaghdha CM, Yang Q, Glazer NL, Leak TS, Dehghan A, Smith AV, Kao WH, Lohman K, Hwang SJ, Johnson AD, et al GEFOS Consortium: Common variants in the calcium-sensing receptor gene are associated with total serum calcium levels. Hum Mol Genet. 19:4296–4303. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chou YH, Woon PY, Chen WC, Hsu YW, Chang JM, Hwang DY, Chiu YC, Kuo HC, Chang WP, Hou MF, et al: A genetic polymorphism (rs17251221) in the calcium-sensing receptor gene (CASR) is associated with stone multiplicity in calcium nephrolithiasis. PLoS One. 6:e252272011. View Article : Google Scholar : PubMed/NCBI
18	Tang Q, Zhao Y, Wang Y and Wei M: A genetic variant (rs17251221) in the calcium-sensing receptor relates to hepatocellular carcinoma susceptibility and clinical outcome treated by transcatheter hepatic arterial chemoembolization (TACE) therapy. Med Oncol. 31:2672014. View Article : Google Scholar : PubMed/NCBI
19	Li X, Kong X, Jiang L, Ma T, Yan S, Yuan C and Yang Q: A genetic polymorphism (rs17251221) in the calcium-sensing receptor is associated with breast cancer susceptibility and prognosis. Cell Physiol Biochem. 33:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
20	Liu X, Zhang N, Li X, Moran MS, Yuan C, Yan S, Jiang L, Ma T, Haffty BG and Yang Q: Identification of novel variants of metadherin in breast cancer. PLoS One. 6:e175822011. View Article : Google Scholar : PubMed/NCBI
21	Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, Yuan C, Moran MS, Liang F, Haffty BG, et al: BCL-2 (−938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 12:482011. View Article : Google Scholar
22	Rodriguez S, Gaunt TR and Day IN: Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 169:505–514. 2009. View Article : Google Scholar : PubMed/NCBI
23	Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA and Wu X: Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem. 60:222–232. 2014. View Article : Google Scholar
24	Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL and Buys SS; Prostate, Lung Colorectal and Ovarian Cancer Project Team: The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol. 110:383–389. 2008. View Article : Google Scholar : PubMed/NCBI
25	Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK and Zwirner M: CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 15:679–691. 2005. View Article : Google Scholar : PubMed/NCBI
26	Aggarwal A, Prinz-Wohlgenannt M, Tennakoon S, Höbaus J, Boudot C, Mentaverri R, Brown EM, Baumgartner-Parzer S and Kállay E: Calcium-sensing receptor: A promising target for prevention of colorectal cancer. Biochim Biophys Acta. Feb 18–2015.Epub ahead of print. View Article : Google Scholar
27	Liu G, Hu X and Chakrabarty S: Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells. Cell Calcium. 45:216–225. 2009. View Article : Google Scholar